NCT01262651View on ClinicalTrials.gov

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

397

Participants

Timeline

Start Date

November 25, 2010

Primary Completion Date

July 2, 2015

Study Completion Date

July 2, 2015

Conditions
PainAdvanced Cancer
Interventions
DRUG

Nabiximols

DRUG

Placebo (GA-0034)

Trial Locations (72)

1000

Brussels

5300

Gabrovo

9010

Varna

9700

Shumen

19146

Philadelphia

27103

Winston-Salem

28739

Hendersonville

30265

Newnan

30281

Stockbridge

32117

Daytona Beach

32257

Jacksonville

32444

Lynn Haven

32789

Winter Park

33511

Brandon

34691

Holiday

34994

Stuart

35578

Wetzlar

44534

Lünen

55426

Saint Louis Park

64132

Kansas City

71105

Shreveport

77024

Houston

77089

Houston

78041

Laredo

84112

Salt Lake City

84124

Salt Lake City

85027

Phoenix

85028

Phoenix

92020

El Cajon

95020

Gilroy

200385

Craiova

410469

Oradea

430031

Baia Mare

440055

Satu Mare

720237

Suceava

810325

Brăila

08009

Berlin

370 01

České Budějovice

370 87

České Budějovice

500 05

Hradec Králové

434 64

Most

262 04

Nová Ves pod Pleší

708 52

Ostrava-Poruba

304 60

Pilsen

07646

Stadtroda

H-6772

Deszk

H-6000

Kecskemét

H-2900

Komárom

H-3501

Miskolc

H-4412

Nyíregyháza

H-7100

Szekszárd

LV-4600

Rēzekne

LV-1079

Riga

LT-92288

Klaipėda

LT-76307

Šiauliai

LT-08660

Vilnius

15-250

Bialystok

43-300

Bielsko-Biala

44-101

Gliwice

61-245

Poznan

02-781

Warsaw

00717

Ponce

00927

San Juan

010976

Bucharest

BL9 7TD

Bury

IP33 2QZ

Bury St Edmunds

EH4 2XR

Edinburgh

G12 0YN

Glasgow

M8 5RB

Manchester

NR4 7UY

Norwich

BS23 4TQ

Weston-super-Mare

WV10 0QP

Wolverhampton

Sponsors
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

lead

GW Pharmaceuticals Ltd

INDUSTRY